Search is Powered by Google
Cancer / Oncology News

Blue Cross Blue Shield Of Michigan-American Society Of Clinical Oncology Initiative To Reduce Costs, Improve Patient Care

Main Category: Cancer / Oncology
Also Included In: Health Insurance / Medical Insurance
Article Date: 12 Aug 2008 - 8:00 PDT

email icon email to a friend   printer icon printer friendly   write icon view / write opinions   rate icon rate article
Current Article Ratings:

Patient / Public:not yet rated

Health Professional:not yet rated

Article Opinions: 0 posts

Blue Cross Blue Shield of Michigan and the American Society of Clinical Oncology are collaborating to collect and analyze treatment information on tens of thousands of people with cancer in Michigan in an effort to improve care and reduce costs, the Detroit News reports. According to BCBS officials, similar initiatives have reduced hospital deaths and saved millions of dollars in unnecessary medical expenses. The effort also is a way for the insurer to become more involved in the delivery of care, according to the News. Thomas Simmer, BCBS' senior vice president and chief medical officer, said, "Its main focus is on quality, but we recognize that we may save some costs for customers."

For the initiative, the groups will collect data from 11 oncology practices in Michigan that account for 180 physicians treating 16,000 patients annually. The data will be entered into ASCO's national registry, which includes information about a number of aspects of cancer treatment, including chemotherapy-related side effects and pain management, from 25,000 cancer professionals at about 385 oncology practices.

Physicians who provide data will receive $3,000 apiece. BCBS says it plans to spend approximately $500,000 this year on the project. According to ASCO CEO Allen Lichter, BCBS is the first insurer to help its physicians offset the costs of collecting and compiling treatment information. According to BCBS spokesperson Helen Stojic, although data collection began in May, the insurer will not know what the exact savings are for about 18 months, although preliminary results will be available in September.

According to Douglas Blayney, medical director of the University of Michigan's Comprehensive Cancer Center and president-elect of ASCO, the project will give physicians in the state a more accurate way to compare their treatments to physicians nationwide, which could improve treatment effectiveness. He said, "This program should help every oncologist measure the quality of the product they are providing" (Rogers, Detroit News, 8/8).

Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation.

© 2008 Advisory Board Company and Kaiser Family Foundation. All rights reserved.




Customized Homepage Weekly Newsletters Daily News Alerts
Home About Us News Licensing Free Website Feeds Free Tools & Content Links Tell a Friend Accessibility Help / FAQ Article Submission Contact Us
Psychiatry Urology
Bipolar Diabetes Schizophrenia

add medical news today to your facebook

medical news gadget

Add to Google


developers
website gadget code
website news code
medical news rss feed links


MedReader RSS Reader

customize your homepage


These are the most read articles from this news category for the last 6 months:
Top Article Star
Shocking Pictures To Appear On Cigarette Packets In UK On 1st October
27 Sep 2008
The UK's ten million Smokers may see pictures of rotting teeth, throat cancer, and indications of male impotence (erectile dysfunction) on cigarette packets they buy at the beginning of October...


Monitoring and Adherence in CML image Monitoring and Adherence in CML

Imatinib, or Gleevec, is a targeted anti-cancer drug that can keep chronic myelogenous leukemia (CML) in check for most patients for many years. It is important for patients to take imatinib as prescribed by their doctor to fight the disease and to guard against resistance...

Treating HER2+ Breast Cancer image Treating HER2+ Breast Cancer

There are at least four different kinds of breast cancer and each is treated differently. For HER2+ breast cancer, a chemotherapy drug is typically the best option. Here's an overview of the drugs used to treat breast cancer...

View more videos...